RCKT
NASDAQ · Biotechnology
Rocket Pharmaceuticals Inc
$4.14
-0.25 (-5.69%)
Financial Highlights (FY 2025)
Revenue
67.67M
Net Income
-17,020,193
Gross Margin
52.9%
Profit Margin
-25.2%
Rev Growth
+1.5%
D/E Ratio
1.36
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 52.9% | 52.9% | 52.9% |
| Operating Margin | -28.0% | -22.4% | -24.2% |
| Profit Margin | -25.2% | -23.9% | -23.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 67.67M | 66.73M | 71.52M |
| Gross Profit | 35.82M | 35.32M | 37.86M |
| Operating Income | -18,937,385 | -14,975,281 | -17,289,655 |
| Net Income | -17,020,193 | -15,934,880 | -16,470,876 |
| Gross Margin | 52.9% | 52.9% | 52.9% |
| Operating Margin | -28.0% | -22.4% | -24.2% |
| Profit Margin | -25.2% | -23.9% | -23.0% |
| Rev Growth | +1.5% | +16.6% | +10.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 145.35M | 132.63M | 149.10M |
| Total Equity | 106.88M | 109.90M | 114.67M |
| D/E Ratio | 1.36 | 1.21 | 1.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -23,292,743 | -22,716,839 | -22,207,941 |
| Free Cash Flow | -11,691,320 | -15,075,459 | -16,131,538 |